Novel therapeutic approach against receptor for advanced glycation end products in patients with diabetic nephropathy or RPGN.

晚期糖基化终末产物（AGEs）及其受体（AGEs）在糖尿病肾病中起重要作用。我们研究了AGE-和RAGE-适体对KKAy/Ta小鼠肾损伤的影响。KKAy/Ta小鼠肾小球AGEs水平显著升高，AGEs-适配体阻断了这一过程。AGEs-适配体可使尿白蛋白和8-羟基-2 '-脱氧鸟苷水平升高，并可防止肾小球肥大和细胞外基质积聚。我们目前的数据表明，AGEs-适配体的持续给药可能是一种可行的和有前途的治疗糖尿病肾病的治疗策略。

Advanced glycation end products (AGEs) and their receptor (RAGE) play a role in diabetic nephropathy. We examined effects of AGE- and RAGE-aptamer on renal injury in KKAy/Ta mice. Glomerular AGEs levels were significantly increased in KKAy/Ta mice, which were blocked by AGEs-aptamer. Urinary albumin and 8-hydroxy-2’-deoxy-guanosine levels were increased, and glomerular hypertrophy and extracellular matrix accumulation were prevented by AGEs-aptamer. Our present data suggest that continuous administration of AGEs-aptamer may be a feasible and promising therapeutic strategy for the treatment of diabeticnephropathy.